William Garrett Gray Sells 12,322 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 12,322 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total value of $49,904.10. Following the transaction, the chief financial officer now directly owns 1,446,322 shares of the company’s stock, valued at $5,857,604.10. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

William Garrett Gray also recently made the following trade(s):

• On Thursday, February 6th, William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics stock. The shares were sold at an average price of $3.67, for a total value of $271,983.70.

Checkpoint Therapeutics Stock Performance

NASDAQ:CKPT opened at $4.01 on Friday. Checkpoint Therapeutics, Inc. has a 52-week low of $1.38 and a 52-week high of $4.50. The firm has a market capitalization of $195.82 million, a PE ratio of -2.18 and a beta of 1.21. The stock has a 50-day simple moving average of $3.42 and a two-hundred day simple moving average of $3.31.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its earnings results on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.47). The company had revenue of $0.04 million for the quarter. Equities analysts forecast that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. HC Wainwright restated a “neutral” rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th. D. Boral Capital reiterated a “buy” rating and set a $4.80 target price on shares of Checkpoint Therapeutics in a report on Monday, March 31st. Finally, Lake Street Capital restated a “hold” rating and issued a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CKPT. Wealth Enhancement Advisory Services LLC raised its position in shares of Checkpoint Therapeutics by 226.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 425,000 shares of the company’s stock valued at $1,360,000 after buying an additional 295,000 shares during the last quarter. Ameriflex Group Inc. bought a new stake in Checkpoint Therapeutics in the 4th quarter valued at $32,000. Squarepoint Ops LLC bought a new stake in Checkpoint Therapeutics in the 4th quarter valued at $230,000. Two Sigma Investments LP lifted its stake in Checkpoint Therapeutics by 73.8% in the 4th quarter. Two Sigma Investments LP now owns 73,032 shares of the company’s stock worth $234,000 after purchasing an additional 31,002 shares in the last quarter. Finally, Man Group plc bought a new position in shares of Checkpoint Therapeutics during the 4th quarter valued at about $35,000. 22.00% of the stock is owned by hedge funds and other institutional investors.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.